A Randomized Trial of Clindamycin Versus Trimethoprim-sulfamethoxazole for Uncomplicated Wound Infection

David A. Talan, Frank Lovecchio, Fredrick M. Abrahamian, David J. Karras, Mark T. Steele, Richard Rothman, Anusha Krishnadasan, William R. Mower, Rebecca Hoagland, Gregory J. Moran

Research output: Contribution to journalArticle

Abstract

Background. With the emergence of community-associated methicillin-resistant Staphylococcus aureus (MRSA) in the United States, visits for skin infections greatly increased. Staphylococci and streptococci are considered predominant causes of wound infections. Clindamycin and trimethoprim-sulfamethoxazole (TMP-SMX) are commonly prescribed, but the efficacy of TMP-SMX has been questioned. Methods. We conducted a randomized, double-blind, superiority trial at 5 US emergency departments. Patients >12 years of age with an uncomplicated wound infection received oral clindamycin 300 mg 4 times daily or TMP-SMX 320 mg/1600 mg twice daily, each for 7 days. We compared the primary outcome, wound infection cure at 7-14 days, and secondary outcomes through 6-8 weeks after treatment, in the per-protocol population. Results. Subjects had a median age of 40 years (range, 14-76 years); 40.1% of wound specimens grew MRSA, 25.7% methicillin-susceptible S. aureus, and 5.0% streptococci. The wound infection was cured at 7-14 days in 187 of 203 (92.1%) clindamycin-treated and 182 of 198 (91.9%) TMP-SMX-treated subjects (difference, 0.2%; 95% confidence interval [CI], -5.8% to 6.2%; P = not significant). The clindamycin group had a significantly lower rate of recurrence at 7-14 days (1.5% vs 6.6%; difference, -5.1%; 95% CI, -9.4% to -.8%) and through 6-8 weeks following treatment (2.0% vs 7.1%; difference, -5.1%; 95% CI, -9.7% to -.6%). Other secondary outcomes were statistically similar between groups but tended to favor clindamycin. Adverse event rates were similar. Conclusions. In settings where MRSA is prevalent, clindamycin and TMP-SMX produce similar cure and adverse event rates among patients with an uncomplicated wound infection. Further study evaluating differential effects of antibiotics on recurrent infection may be warranted. Clinical Trials Registration. NCT00729937.

Original languageEnglish (US)
Pages (from-to)1505-1513
Number of pages9
JournalClinical Infectious Diseases
Volume62
Issue number12
DOIs
StatePublished - Jun 15 2016

Fingerprint

Clindamycin
Sulfamethoxazole Drug Combination Trimethoprim
Wound Infection
Methicillin-Resistant Staphylococcus aureus
Confidence Intervals
Streptococcus
Methicillin
Infection
Staphylococcus
Staphylococcus aureus
Hospital Emergency Service
Clinical Trials
Anti-Bacterial Agents
Recurrence
Skin
Wounds and Injuries
Therapeutics
Population

Keywords

  • clindamycin
  • methicillin-resistant Staphylococcus aureus
  • randomized
  • trimethoprim-sulfamethoxazole
  • wound infection

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)

Cite this

Talan, D. A., Lovecchio, F., Abrahamian, F. M., Karras, D. J., Steele, M. T., Rothman, R., ... Moran, G. J. (2016). A Randomized Trial of Clindamycin Versus Trimethoprim-sulfamethoxazole for Uncomplicated Wound Infection. Clinical Infectious Diseases, 62(12), 1505-1513. https://doi.org/10.1093/cid/ciw177

A Randomized Trial of Clindamycin Versus Trimethoprim-sulfamethoxazole for Uncomplicated Wound Infection. / Talan, David A.; Lovecchio, Frank; Abrahamian, Fredrick M.; Karras, David J.; Steele, Mark T.; Rothman, Richard; Krishnadasan, Anusha; Mower, William R.; Hoagland, Rebecca; Moran, Gregory J.

In: Clinical Infectious Diseases, Vol. 62, No. 12, 15.06.2016, p. 1505-1513.

Research output: Contribution to journalArticle

Talan, DA, Lovecchio, F, Abrahamian, FM, Karras, DJ, Steele, MT, Rothman, R, Krishnadasan, A, Mower, WR, Hoagland, R & Moran, GJ 2016, 'A Randomized Trial of Clindamycin Versus Trimethoprim-sulfamethoxazole for Uncomplicated Wound Infection', Clinical Infectious Diseases, vol. 62, no. 12, pp. 1505-1513. https://doi.org/10.1093/cid/ciw177
Talan, David A. ; Lovecchio, Frank ; Abrahamian, Fredrick M. ; Karras, David J. ; Steele, Mark T. ; Rothman, Richard ; Krishnadasan, Anusha ; Mower, William R. ; Hoagland, Rebecca ; Moran, Gregory J. / A Randomized Trial of Clindamycin Versus Trimethoprim-sulfamethoxazole for Uncomplicated Wound Infection. In: Clinical Infectious Diseases. 2016 ; Vol. 62, No. 12. pp. 1505-1513.
@article{c88c78ad9e89425aaafc934e1d70679a,
title = "A Randomized Trial of Clindamycin Versus Trimethoprim-sulfamethoxazole for Uncomplicated Wound Infection",
abstract = "Background. With the emergence of community-associated methicillin-resistant Staphylococcus aureus (MRSA) in the United States, visits for skin infections greatly increased. Staphylococci and streptococci are considered predominant causes of wound infections. Clindamycin and trimethoprim-sulfamethoxazole (TMP-SMX) are commonly prescribed, but the efficacy of TMP-SMX has been questioned. Methods. We conducted a randomized, double-blind, superiority trial at 5 US emergency departments. Patients >12 years of age with an uncomplicated wound infection received oral clindamycin 300 mg 4 times daily or TMP-SMX 320 mg/1600 mg twice daily, each for 7 days. We compared the primary outcome, wound infection cure at 7-14 days, and secondary outcomes through 6-8 weeks after treatment, in the per-protocol population. Results. Subjects had a median age of 40 years (range, 14-76 years); 40.1{\%} of wound specimens grew MRSA, 25.7{\%} methicillin-susceptible S. aureus, and 5.0{\%} streptococci. The wound infection was cured at 7-14 days in 187 of 203 (92.1{\%}) clindamycin-treated and 182 of 198 (91.9{\%}) TMP-SMX-treated subjects (difference, 0.2{\%}; 95{\%} confidence interval [CI], -5.8{\%} to 6.2{\%}; P = not significant). The clindamycin group had a significantly lower rate of recurrence at 7-14 days (1.5{\%} vs 6.6{\%}; difference, -5.1{\%}; 95{\%} CI, -9.4{\%} to -.8{\%}) and through 6-8 weeks following treatment (2.0{\%} vs 7.1{\%}; difference, -5.1{\%}; 95{\%} CI, -9.7{\%} to -.6{\%}). Other secondary outcomes were statistically similar between groups but tended to favor clindamycin. Adverse event rates were similar. Conclusions. In settings where MRSA is prevalent, clindamycin and TMP-SMX produce similar cure and adverse event rates among patients with an uncomplicated wound infection. Further study evaluating differential effects of antibiotics on recurrent infection may be warranted. Clinical Trials Registration. NCT00729937.",
keywords = "clindamycin, methicillin-resistant Staphylococcus aureus, randomized, trimethoprim-sulfamethoxazole, wound infection",
author = "Talan, {David A.} and Frank Lovecchio and Abrahamian, {Fredrick M.} and Karras, {David J.} and Steele, {Mark T.} and Richard Rothman and Anusha Krishnadasan and Mower, {William R.} and Rebecca Hoagland and Moran, {Gregory J.}",
year = "2016",
month = "6",
day = "15",
doi = "10.1093/cid/ciw177",
language = "English (US)",
volume = "62",
pages = "1505--1513",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - A Randomized Trial of Clindamycin Versus Trimethoprim-sulfamethoxazole for Uncomplicated Wound Infection

AU - Talan, David A.

AU - Lovecchio, Frank

AU - Abrahamian, Fredrick M.

AU - Karras, David J.

AU - Steele, Mark T.

AU - Rothman, Richard

AU - Krishnadasan, Anusha

AU - Mower, William R.

AU - Hoagland, Rebecca

AU - Moran, Gregory J.

PY - 2016/6/15

Y1 - 2016/6/15

N2 - Background. With the emergence of community-associated methicillin-resistant Staphylococcus aureus (MRSA) in the United States, visits for skin infections greatly increased. Staphylococci and streptococci are considered predominant causes of wound infections. Clindamycin and trimethoprim-sulfamethoxazole (TMP-SMX) are commonly prescribed, but the efficacy of TMP-SMX has been questioned. Methods. We conducted a randomized, double-blind, superiority trial at 5 US emergency departments. Patients >12 years of age with an uncomplicated wound infection received oral clindamycin 300 mg 4 times daily or TMP-SMX 320 mg/1600 mg twice daily, each for 7 days. We compared the primary outcome, wound infection cure at 7-14 days, and secondary outcomes through 6-8 weeks after treatment, in the per-protocol population. Results. Subjects had a median age of 40 years (range, 14-76 years); 40.1% of wound specimens grew MRSA, 25.7% methicillin-susceptible S. aureus, and 5.0% streptococci. The wound infection was cured at 7-14 days in 187 of 203 (92.1%) clindamycin-treated and 182 of 198 (91.9%) TMP-SMX-treated subjects (difference, 0.2%; 95% confidence interval [CI], -5.8% to 6.2%; P = not significant). The clindamycin group had a significantly lower rate of recurrence at 7-14 days (1.5% vs 6.6%; difference, -5.1%; 95% CI, -9.4% to -.8%) and through 6-8 weeks following treatment (2.0% vs 7.1%; difference, -5.1%; 95% CI, -9.7% to -.6%). Other secondary outcomes were statistically similar between groups but tended to favor clindamycin. Adverse event rates were similar. Conclusions. In settings where MRSA is prevalent, clindamycin and TMP-SMX produce similar cure and adverse event rates among patients with an uncomplicated wound infection. Further study evaluating differential effects of antibiotics on recurrent infection may be warranted. Clinical Trials Registration. NCT00729937.

AB - Background. With the emergence of community-associated methicillin-resistant Staphylococcus aureus (MRSA) in the United States, visits for skin infections greatly increased. Staphylococci and streptococci are considered predominant causes of wound infections. Clindamycin and trimethoprim-sulfamethoxazole (TMP-SMX) are commonly prescribed, but the efficacy of TMP-SMX has been questioned. Methods. We conducted a randomized, double-blind, superiority trial at 5 US emergency departments. Patients >12 years of age with an uncomplicated wound infection received oral clindamycin 300 mg 4 times daily or TMP-SMX 320 mg/1600 mg twice daily, each for 7 days. We compared the primary outcome, wound infection cure at 7-14 days, and secondary outcomes through 6-8 weeks after treatment, in the per-protocol population. Results. Subjects had a median age of 40 years (range, 14-76 years); 40.1% of wound specimens grew MRSA, 25.7% methicillin-susceptible S. aureus, and 5.0% streptococci. The wound infection was cured at 7-14 days in 187 of 203 (92.1%) clindamycin-treated and 182 of 198 (91.9%) TMP-SMX-treated subjects (difference, 0.2%; 95% confidence interval [CI], -5.8% to 6.2%; P = not significant). The clindamycin group had a significantly lower rate of recurrence at 7-14 days (1.5% vs 6.6%; difference, -5.1%; 95% CI, -9.4% to -.8%) and through 6-8 weeks following treatment (2.0% vs 7.1%; difference, -5.1%; 95% CI, -9.7% to -.6%). Other secondary outcomes were statistically similar between groups but tended to favor clindamycin. Adverse event rates were similar. Conclusions. In settings where MRSA is prevalent, clindamycin and TMP-SMX produce similar cure and adverse event rates among patients with an uncomplicated wound infection. Further study evaluating differential effects of antibiotics on recurrent infection may be warranted. Clinical Trials Registration. NCT00729937.

KW - clindamycin

KW - methicillin-resistant Staphylococcus aureus

KW - randomized

KW - trimethoprim-sulfamethoxazole

KW - wound infection

UR - http://www.scopus.com/inward/record.url?scp=84965016698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965016698&partnerID=8YFLogxK

U2 - 10.1093/cid/ciw177

DO - 10.1093/cid/ciw177

M3 - Article

VL - 62

SP - 1505

EP - 1513

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 12

ER -